Full Press Release Details
Biosciences Relocates Corporate Headquarters to Cambridge, MA
aligns with company's vision to leverage the Greater Boston biotech hub's scientific and financial ecosystem and advance
EB-003 into first-in-human trial in 2026
Mass., September 2, 2025 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"),
a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders,
today announced the relocation of its corporate headquarters to Cambridge, Massachusetts, 02142.
believes the move will foster stronger collaborations, facilitate top-tier talent recruitment, and enhance visibility within one of the
world's most vibrant life sciences clusters where world-class scientific expertise, leading biopharma companies, premier academic
institutions, and a dynamic investor community converge.
our headquarters to Cambridge represents an important step in Enveric's growth trajectory," said Joseph Tucker, Ph.D., Director
and CEO of Enveric. "The Greater Boston biotech hub offers unparalleled access to scientific innovation, industry leadership, and
capital markets. These advantages will be beneficial as we prepare to advance our lead molecule, EB-003, into first-in-human clinical
trials and pursue our vision of transforming the treatment landscape for patients living with serious neuropsychiatric conditions."
is designed to deliver the therapeutic benefits of neuroplastogens while minimizing hallucinatory effects. Enveric recently unveiled
that its lead development candidate, EB-003, is believed to be the first representative of a novel potential pharmacological class of
neuroplastogens, defined by dual engagement of the 5-HT A and 5-HT B receptors. With encouraging preclinical
data supporting its differentiated profile, the company is advancing EB-003 toward an Investigational New Drug (IND) submission, with
first-in-human studies anticipated in 2026.
Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics
that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing
library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without
hallucinogenic effects. Enveric's lead candidate, EB-003, is the first known compound designed to selectively engage both
5-HT A and 5-HT B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with
outpatient convenience.
more information, please visit www.enveric.com.
press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These
statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking
statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology
such as "plans," "expects" or "does not expect," "proposes," "budgets," "explores,"
"schedules," "seeks," "estimates," "forecasts," "intends," "anticipates"
or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases
which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements
may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management
as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated
by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize
and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation
contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or
safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate
or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on
commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors;
hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent
protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a
going concern; and manage its future growth effectively.
discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings
with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by law.
Strategic Advisors, Inc.
Strategic Advisors, Inc.